Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Journey Medical Corp ( (DERM) ) has shared an update.
On June 24, 2025, Journey Medical Corporation held its 2025 Annual Meeting of Stockholders, where stockholders approved three key proposals. These included the election of six directors, the ratification of KPMG LLP as the independent registered public accounting firm for 2025, and the approval of the Fourth Amended and Restated Certificate of Incorporation, which includes provisions for officer exculpation.
The most recent analyst rating on (DERM) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Journey Medical Corp stock, see the DERM Stock Forecast page.
Spark’s Take on DERM Stock
According to Spark, TipRanks’ AI Analyst, DERM is a Neutral.
Journey Medical Corp faces significant financial challenges, primarily due to declining revenues and negative profitability. However, recent strategic initiatives and product launches provide a positive outlook, supported by improved market positioning and financial metrics. The stock’s technical indicators are mixed, and the valuation remains a concern due to losses. The overall score reflects a cautious optimism based on potential growth catalysts.
To see Spark’s full report on DERM stock, click here.
More about Journey Medical Corp
Average Trading Volume: 102,973
Technical Sentiment Signal: Buy
Current Market Cap: $162.4M
Learn more about DERM stock on TipRanks’ Stock Analysis page.